Summary
Many of the biological activities of cytokines are similar to clinical manifestations and abnormalities of laboratory parameters observed in chronic liver diseases (CLD). Evidence of impaired cytokine synthesis in CLD comes from studies of serum or plasma levels, supernatants of peripheral blood mononuclear cells stimulated with various agents and from studying cytokine expression locally in the liver. Circulating levels of several cytokine-regulated molecules such as neopterin, soluble IL-2 receptor, adhesion molecules, and metabolites of the nitric oxide pathway are elevated in patients with CLD. Thus inhibition of cytokine synthesis or modulation of their activity could provide not only important information about their pathophysiologic relevance but also have a profound impact on disease progression in CLD. These studies will also show whether prolonged anti-cytokine treatment with interleukin-1- or tumor necrosis factor-inhibitors interferes with host defense mechanism.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Adams DH, Mainolfi E, Burra P, et al, Detection of circulating intercellular adhesion molecule-1 in chronic liver disease. Hepatology 16: 810, 1992
Anastassakos C, Alexander GJ, Wolstencraft RA, et al, Interleukin-1 and interleukin-2 activity in chronic hepatitis B virus infection. Gastroenterology 94: 999, 1988
Andus T, Bauer J, Gerok W, Effects of cytokines on the liver. Hepatology 13: 364, 1991
Arend WP, Interleukin-1 receptor antagonist. J Clin Invest 88: 1445, 1991
Ashkenazi A, Marsters SA, Capon DJ, et al, Protection against endotoxic shock by a human tumor necrosis factor receptor immunoadhesion. Proc Natl Acad Sci USA 88: 10535, 1991
Bemelmanns MHA, Gouma DJ, Greve JW, et al., Cytokines tumor, necrosis factor and interleukin-6 in experimental biliary obstruction in mice. Hepatology 15:1132, 1992
Billiau A, Matthys P, Interferon-gamma, more of a cachectin than tumor necrosis factor. Cytokine 4:259, 1992.
Bissel DM, Roll J, Connective tissue metabolism and hepatic fibrosis. In: Zakim D, Boyer TD (eds) Hepatology 2nd edn. Saunders, Philadelphia, 1990.
Ceretti DP, Kozlovsky CJ, Mosley B, et al., Molecular cloning of the interleukin-1β converting enzyme. Science 256:97, 1992
Cobb JP, Natanson C, Hoffman WD, et al., N-Amino-L-Arginine, an inhibitor of nitric oxide synthase, raises vascular resistance but increases mortality rates in awake canines challenged with endotoxin. J Exp Med 175:1175, 1992
Czaja MJ, Flanders KC, Biempica L, et al., Expression of tumor necrosis factor-α and transforming growth factor-β in acute liver injury. Growth Factors 1:219, 1989
Daito K, Suou T, Kawasaki H, Clinical significance of serum and urinary neopterin levels in patients with various liver diseases. Am J Gastroenterol 87:471, 1992
Deviere J, Content J, Denys C, et al., High interleukin-6 serum levels and increased production by leukocytes in alcoholic liver cirrhosis. Correlation with IgA serum levels and lymphokine production. Clin Exp Immunol 77:221, 1989
Deviere J, Content J, Denys C, et al., Excessive in vitro bacterial lipopolysaccharide-induced production of monokines in cirrhosis. Hepatology 11:628, 1990
Dinarello CA, Interleukin-1 and interleukin-1 antagonism. Blood 77:1627, 1991
Dinarello CA, Thompson RC, Blocking IL-1 interleukin-1 receptor antagonist in vitro and in vivo. Immunol Today 12:404, 1991
Dinarello CA, Wolff SM, The role of interleukin-1 in diesease. N Engl J Med 328:106, 1993
Dufour JF, Arias IM, Nitric oxide inhibits bile canalicular contraction: a potential cholestatic mechanism (abstract). Hepatology 16:126A, 1992
Fisher B, Keenan AM, Garra BS, et al., Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients. J Clin Oncol 12:1852, 1989
Flynn RM, Palladino MA, TNF and TGF-β: the opposite sides of the avenue? In: Beutler B (ed) Tumor necrosis factors: the molecules and their emerging role in medicine. Raven, New York, pp. 131–144, 1992.
Frizell E, Degli-Esposti S, Manning P, et al., IL-1 receptor anatagonist therapy of hepatic fibrosis (abstract). Hepatology 16:182A, 1992
Fuji A, Kakumu S, Ohtani Y, et al., Interferon-gamma production by peripheral blood mononuclear cells of patients with chronic liver disease. Hepatology 7:577, 1987
Gershenwald JE, Fong YM, Fahey TJ III, et al., Interleukin-1 receptor blockade attenuates the host inflammatory response. Proc Natl Acad Sci USA 87:4966, 1990
Ghezzi P, TNF and the liver. In: Beutler B (ed) Tumor necrosis factors: the molecules and their emerging role in medicine. Raven, New York, 1992
Henderson B, Blake S, Therapeutic potential of cytokine manipulation. Trends Pharmacol Sci 13:145, 1992
Hirano T, Interleukin-6. In: Thomson A (ed) The cytokine handbook. Academic Press, New York, pp 169–190, 1992
Hunt NC, Goldin RD, Nitric oxide production by monocytes in alcoholic liver disease. J Hepatol 14:146, 1992
Khoruts A, Stahnke L, McClain CJ, et al., Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentration in chronic alcoholic patients. Hepatology 13:267, 1991
Kohno T, Brewer MT, Baker SL, et al., A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Proc Natl Acad Sci USA 87:8331, 1990.
Kovacs EJ, Fibrogenetic cytokines: the role of immune mediators in the development of scar tissue. Immunol Today 12:17, 1991.
Lötscher H, Pan YE, Lahm H-W, et al., Molecular cloning and expression of the human 55kD tumor necrosis factor receptor. Cell 61:351, 1990.
Mancine R, Jezequel AM, Marucci L, et al., Interleukin-1 receptor antagonist (IL-1Ra) reduces collagen deposition in experimental hepatic, fibrosis (abstract). J Hepatol 16 [Suppl 1]: S 32, 1992
Mori M, Yamaguchi H, Honda S, et al., Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia-inhibitory factor. Cancer Res 51:6656, 1991
Müller C, Zielinski CC, Interleukin-6 production by peripheral blood monocytes in patients with chronic liver disease and acute viral hepatitis. J Hepatol 15:372, 1992
Müller C, Knoflach P, Zielinski CC, Solube interleukin-2 receptor in acute viral hepatitis and chronic liver disease. Hepatology 10:928, 1989
Munoz C, Carlet J, Fitting C, et al., Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 88:1747, 1991
Nathan C, Nitric oxide as a secretory product of mammlian cells. FASEB J 6:3051, 1992
Nophar, Y, Kemper O, Brakebusch C, et al., Soluble forms of tumor necrosis factor receptor (TNF-Rs). The cDNA for the type 1 TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J 9:3269, 1990
Nussler AK, Di Silvio M, Billiar R, et al., Stimulation of the nitric oxide synthase pathway in human hepatocytes by cytokines and endotoxin. J Exp Med 176:261, 1992
Oliff A, Defeo-Jones D, Boyer M, et al., Tumors secreting human TNF/cachectin induced cachexia in mice. Cell 50:555, 1987
Peterson TC, Isbrucker RA, Fibroproliferation in liver disease: role of monocyte factors. Hepatology 15:191, 1992
Porteu F, Brockhaus M, Wallach D, et al., Human neutrophil elastase releases a ligand-binding fragment from the 75-kD tumor necrosis factor (TNF) receptor. J Biol Chem 266:18 846, 1991.
Schall TJ, Lewis M, Koller KJ, et al., Molecular cloning and expression of a receptor for human necrosis factor. Cell 6:361, 1990
Seckinger P, Isaaz S, Dayer J-M, a human inhibitor of tumor necrosis factor α. J Exp Med 168:1511, 1988
Sherlock S, Dooley J, Diseases of the liver and biliary system. Blackwell, Oxford, 1993
Sheron N, Lau J, Daniels H, et al., Increased production of tumour necrosis factor alpha in chronic hepatitis B virus infection. J Hepatol 12:241, 1991
Sherry BA, Gellin J, Fong Y, et al., Anticachectin/tumor necrosis factor-α antibodies, attenuate development of cachexia in tumor models. FASEB J 3:1956, 1989.
Shultz PJ, Raji L, Endogenously synthesized nitric oxide prevents endotoxin-induced glomerular thrombosis. J Clin Invest 90:1718, 1992
Stark ME, Szurszewski JH, Role of nitric oxide in gastrointestinal and hepatic function and disease. Gastroenterology 103:1928, 1992
Strassmann G, Fong M, Kenney JS, et al., Evidence for the involvement of interleukin-6 in experimental cancer cachexia. J Clin Invest 89:1681, 1992
Thomson A, The cytokine handbook. Academic Press, New York, 1992
Thornberry NA, Bull HG, Calaycay JR, et al., A novel heterodimeric cysteine protease is required for interleukin-1β processing in monocytes. Nature 356:768, 1992
Tilg H, Wilmer A, Vogel W, et al., Serum levels of cytokines in chronic liver diseases. Gastroenterology 103:264, 1992
Tilg H, Shapiro L, Atkins MB, et al., Induction of circulating and erythrocyte-bound IL-8 by IL-2 immunotherapy and suppression of its in vitro production by IL-1 receptor antagonist and soluble TNF receptor p75-chimera. J Immunol (in press)
TilgeH, Vogel W, Wiedermann CJ, et al., Circulating IL-1 and TNF antagnoists in liver diseases. Heaptology (in press)
Thomas A, Soriano G, Guarner C, et al., Increased serum nitrite and nitrate in cirrhosis. Relationship to endotoxemia (abstract). J Hepatol 16 [Supp 1]: S 40, 1992
Toth CA, Thomas P, Liver endocytosis and Kupffer cells. Hepatology 16:255, 1992
Tracey KJ, Wei H, Manogue KR, et al., Cachectin/tumor necrosis factor induces cachexia, anemia and inflammation. J Exp Med 167:1211, 1988
Tracey KJ, Morgello S, Koplin B, et al., Metabolic effects of chachectin/tumor necrosis factor are modified by site of production: cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantly acute anorexia. J Clin Invest 86:2014, 1990.
Triger D, Wright R, Hyperglobulinaemia in liver disease. Lancet I:1494, 1973
Vassalli P, The pathophysiology of tumor necrosis factors. Ann Rev Immunol 10:411, 1992
Volpes R, Oord JJ van den, De Vos R, et al., Hepatic expression of type A and type B receptors for tumor necrosis factor. J Hepatol 14:361, 1992
Wachter H, Fuchs D, Hausen D, et al., Neopterin as marker for activation of cellular immunity: immunological basis and clinical application. Adv Clin Chem 27:82, 1989
Whittle BJR, Moncada S, Nitric oxide: the elusive mediator of the hyperdynamic circulation of cirrhosis? Hepatology 16:1089, 1992
Yokota M, Sakamato S, Koga S, et al., Decreased interleukin-1 activity in culture supernatent of lipopolysaccharide-stimulated monocytes from patients with liver cirrhosis and hepatocellular carcinoma. Clin Exp Immunol 67:335, 1987
Yoshioka K, Kakumu S, Arao M, et al., Tumor necrosis factor α production by peripheral blood mononuclear cells of patients with chronic liver disease. Hepatology 10:769, 1989
Yoshioka K, Kakumu S, Arao M, et al., Immunohistochemical studies of intrahepatic tumour necrosis factor α in chronic liver disease. J Clin Pathol 43:298, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tign, H. The role of cytokines in the pathophysiology of chronic liver diseases. Int J Clin Lab Res 23, 179–185 (1993). https://doi.org/10.1007/BF02592306
Issue Date:
DOI: https://doi.org/10.1007/BF02592306